vs

Side-by-side financial comparison of PROCEPT BioRobotics Corp (PRCT) and ZK International Group Co., Ltd. (ZKIN). Click either name above to swap in a different company.

ZK International Group Co., Ltd. is the larger business by last-quarter revenue ($108.2M vs $83.1M, roughly 1.3× PROCEPT BioRobotics Corp). ZK International Group Co., Ltd. runs the higher net margin — -2.6% vs -38.1%, a 35.5% gap on every dollar of revenue.

PROCEPT BioRobotics Corp is a medical tech firm developing and commercializing robotic surgical solutions for urological care. Its flagship AquaBeam system provides image-guided minimally invasive therapy for benign prostatic hyperplasia, serving providers and patients across North America, Europe and global markets.

ZK International Group Co., Ltd. is a China-based enterprise focused on the research, development, design, manufacturing and sale of high-quality stainless steel piping systems and fluid transport supporting products. Its offerings cater to construction, municipal infrastructure and residential engineering segments, with core markets spanning China and selected overseas regions.

PRCT vs ZKIN — Head-to-Head

Bigger by revenue
ZKIN
ZKIN
1.3× larger
ZKIN
$108.2M
$83.1M
PRCT
Higher net margin
ZKIN
ZKIN
35.5% more per $
ZKIN
-2.6%
-38.1%
PRCT

Income Statement — Q1 FY2026 vs Q4 FY2024

Metric
PRCT
PRCT
ZKIN
ZKIN
Revenue
$83.1M
$108.2M
Net Profit
$-31.6M
$-2.8M
Gross Margin
64.9%
6.1%
Operating Margin
-4.1%
-1.6%
Net Margin
-38.1%
-2.6%
Revenue YoY
20.2%
Net Profit YoY
-27.9%
EPS (diluted)
$-0.56
$-0.57

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PRCT
PRCT
ZKIN
ZKIN
Q1 26
$83.1M
Q4 25
$76.4M
Q3 25
$83.3M
Q2 25
$79.2M
Q1 25
$69.2M
Q4 24
$68.2M
Q3 24
$58.4M
$108.2M
Q2 24
$53.4M
Net Profit
PRCT
PRCT
ZKIN
ZKIN
Q1 26
$-31.6M
Q4 25
$-29.8M
Q3 25
$-21.4M
Q2 25
$-19.6M
Q1 25
$-24.7M
Q4 24
$-18.9M
Q3 24
$-21.0M
$-2.8M
Q2 24
$-25.6M
Gross Margin
PRCT
PRCT
ZKIN
ZKIN
Q1 26
64.9%
Q4 25
60.6%
Q3 25
64.8%
Q2 25
65.4%
Q1 25
63.9%
Q4 24
64.0%
Q3 24
63.2%
6.1%
Q2 24
59.0%
Operating Margin
PRCT
PRCT
ZKIN
ZKIN
Q1 26
-4.1%
Q4 25
-40.6%
Q3 25
-27.8%
Q2 25
-28.0%
Q1 25
-39.7%
Q4 24
-28.9%
Q3 24
-38.4%
-1.6%
Q2 24
-50.3%
Net Margin
PRCT
PRCT
ZKIN
ZKIN
Q1 26
-38.1%
Q4 25
-39.1%
Q3 25
-25.7%
Q2 25
-24.7%
Q1 25
-35.8%
Q4 24
-27.6%
Q3 24
-35.9%
-2.6%
Q2 24
-48.0%
EPS (diluted)
PRCT
PRCT
ZKIN
ZKIN
Q1 26
$-0.56
Q4 25
$-0.54
Q3 25
$-0.38
Q2 25
$-0.35
Q1 25
$-0.45
Q4 24
$-0.34
Q3 24
$-0.40
$-0.57
Q2 24
$-0.50

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PRCT
PRCT
ZKIN
ZKIN
Cash + ST InvestmentsLiquidity on hand
$245.6M
$4.1M
Total DebtLower is stronger
$51.7M
Stockholders' EquityBook value
$347.7M
$28.2M
Total Assets
$487.1M
$80.0M
Debt / EquityLower = less leverage
0.15×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PRCT
PRCT
ZKIN
ZKIN
Q1 26
$245.6M
Q4 25
$286.5M
Q3 25
$294.3M
Q2 25
$302.7M
Q1 25
$316.2M
Q4 24
$333.7M
Q3 24
$196.8M
$4.1M
Q2 24
$214.1M
Total Debt
PRCT
PRCT
ZKIN
ZKIN
Q1 26
$51.7M
Q4 25
$51.6M
Q3 25
$51.6M
Q2 25
$51.5M
Q1 25
$51.5M
Q4 24
$51.5M
Q3 24
$51.4M
Q2 24
$51.4M
Stockholders' Equity
PRCT
PRCT
ZKIN
ZKIN
Q1 26
$347.7M
Q4 25
$365.9M
Q3 25
$380.3M
Q2 25
$385.8M
Q1 25
$389.2M
Q4 24
$402.2M
Q3 24
$241.2M
$28.2M
Q2 24
$251.8M
Total Assets
PRCT
PRCT
ZKIN
ZKIN
Q1 26
$487.1M
Q4 25
$508.1M
Q3 25
$511.5M
Q2 25
$513.1M
Q1 25
$519.4M
Q4 24
$534.0M
Q3 24
$374.1M
$80.0M
Q2 24
$374.4M
Debt / Equity
PRCT
PRCT
ZKIN
ZKIN
Q1 26
0.15×
Q4 25
0.14×
Q3 25
0.14×
Q2 25
0.13×
Q1 25
0.13×
Q4 24
0.13×
Q3 24
0.21×
Q2 24
0.20×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PRCT
PRCT
ZKIN
ZKIN
Operating Cash FlowLast quarter
$-6.9M
Free Cash FlowOCF − Capex
$-7.5M
FCF MarginFCF / Revenue
-6.9%
Capex IntensityCapex / Revenue
0.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PRCT
PRCT
ZKIN
ZKIN
Q1 26
Q4 25
$-10.3M
Q3 25
$-6.6M
Q2 25
$-15.0M
Q1 25
$-17.0M
Q4 24
$-32.4M
Q3 24
$-18.8M
$-6.9M
Q2 24
$-15.7M
Free Cash Flow
PRCT
PRCT
ZKIN
ZKIN
Q1 26
Q4 25
$-12.2M
Q3 25
$-9.5M
Q2 25
$-17.8M
Q1 25
$-18.8M
Q4 24
$-33.6M
Q3 24
$-19.0M
$-7.5M
Q2 24
$-16.8M
FCF Margin
PRCT
PRCT
ZKIN
ZKIN
Q1 26
Q4 25
-15.9%
Q3 25
-11.4%
Q2 25
-22.5%
Q1 25
-27.2%
Q4 24
-49.2%
Q3 24
-32.6%
-6.9%
Q2 24
-31.4%
Capex Intensity
PRCT
PRCT
ZKIN
ZKIN
Q1 26
Q4 25
2.4%
Q3 25
3.4%
Q2 25
3.5%
Q1 25
2.7%
Q4 24
1.7%
Q3 24
0.4%
0.6%
Q2 24
2.0%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PRCT
PRCT

Handpieces and other consumables$43.0M52%
System sales and rentals$23.4M28%
Other$11.1M13%
Service$5.6M7%

ZKIN
ZKIN

Segment breakdown not available.

Related Comparisons